Neomorph, Novo Nordisk enter $1.46bn partnership focused on molecular glue degraders
Neomorph will receive upfront and near-term milestone payments, R&D funding, and milestone payments, totalling $1.46bn from Novo Nordisk,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Feb 24
Neomorph will receive upfront and near-term milestone payments, R&D funding, and milestone payments, totalling $1.46bn from Novo Nordisk,…
27 Feb 24
The approval allows the oral suspension to be utilised in treating CLL/ SLL, WM, and cGVHD following the…
27 Feb 24
The latest expanded indication of Biktarvy pertains to the treatment of individuals with HIV who are known or…
27 Feb 24
Gepotidacin is a triazaacenaphthylene antibiotic that acts as a bactericidal agent by hindering bacterial DNA replication through a…
27 Feb 24
The nearly 300,000-square-foot facility will employ 400 full-time staff
26 Feb 24
Simlandi is the first citrate-free, high-concentration biosimilar to be designated interchangeable with Humira in the US, and is…
26 Feb 24
The facility is anticipated to produce respiratory mRNA vaccines for Canadians in 2025 and improve domestic preparedness for…
26 Feb 24
EmVenio's Community Research Site Network helps remove barriers for participation in clinical research for underrepresented communities
23 Feb 24
The collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles platform, to develop novel multifunctional biologics in…
22 Feb 24
In the interim review of the Phase 3 LATITUDE study, performed by the Data Safety Monitoring Board (DSMB),…